Invivoscribe(R) Launches LeukoStrat(R) KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide

Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat(R) KMT2A + MRD Assay and Software to its industry-leading ...
Monthly Prescribing Reference

MRD Is “Credible” Surrogate Endpoint in Acute Myeloid Leukemia

Minimal residual disease was “strongly” associated with overall survival at the patient level, researchers reported. Minimal residual disease (MRD) is “a credible intermediate endpoint” for some ...
Medscape

MRD and Relapse in Patients With AML

This transcript has been edited for clarity. Gail J. Roboz, MD: Hi, everyone. My name is Dr Gail Roboz. I'm a professor of medicine and director of the leukemia program at Weill Cornell Medicine and ...
Medscape

MRD Status Predicts Transplant Benefit in NPM1-Mutated AML

SAN DIEGO — Allogeneic stem cell transplant is associated with a significant survival benefit in patients with NPM1-mutated acute myeloid leukemia (AML) who are in their first complete remission and ...
Targeted Oncology

Early Immune Intervention is Key to Managing Posttransplant Relapse in AML

Timely donor lymphocyte infusion (DLI) following the detection of impending molecular relapse may significantly improve ...
MedPage Today

TBI-Free Conditioning Before Transplant Effective in MRD-Negative B-ALL

ORLANDO -- A conditioning regimen free from total body irradiation (TBI) appeared to be just as effective as standard of care (SoC) in a common type of childhood leukemia, according to a phase II ...